Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 17140356)

1.
2.

A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.

Oh DY, Hurt AC.

Scientifica (Cairo). 2014;2014:430629. doi: 10.1155/2014/430629. Epub 2014 Apr 2. Review.

3.

Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009-2012.

Hoang Vu MP, Nguyen CT, Nguyen le KH, Nguyen TK, Le QM.

Western Pac Surveill Response J. 2013 Jun 26;4(2):25-9. doi: 10.5365/WPSAR.2013.4.1.010. eCollection 2013 Apr-Jun.

4.

Molecular distribution of amino acid substitutions on neuraminidase from the 2009 (H1N1) human influenza pandemic virus.

Quiliano M, Valdivia-Olarte H, Olivares C, Requena D, Gutiérrez AH, Reyes-Loyola P, Tolentino-Lopez LE, Sheen P, Briz V, Muñoz-Fernández MA, Correa-Basurto J, Zimic M.

Bioinformation. 2013 Jul 17;9(13):673-9. doi: 10.6026/97320630009673. Print 2013.

5.

Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.

Hall RJ, Peacey M, Ralston JC, de Joux DJ, Bocacao J, Nicol M, Ziki M, Gunn W, Wang J, Huang QS.

Western Pac Surveill Response J. 2012 Oct 30;3(4):71-7. doi: 10.5365/WPSAR.2012.3.3.002. Print 2012 Oct.

6.

Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study.

Han N, Liu X, Mu Y.

PLoS One. 2012;7(9):e44057. doi: 10.1371/journal.pone.0044057. Epub 2012 Sep 6.

7.

Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic.

Kumar S, Henrickson KJ.

Clin Microbiol Rev. 2012 Apr;25(2):344-61. doi: 10.1128/CMR.05016-11. Review.

8.

Systematic review of influenza resistance to the neuraminidase inhibitors.

Thorlund K, Awad T, Boivin G, Thabane L.

BMC Infect Dis. 2011 May 19;11:134. doi: 10.1186/1471-2334-11-134. Review.

9.

Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.

Hurt AC, Nor'e SS, McCaw JM, Fryer HR, Mosse J, McLean AR, Barr IG.

J Virol. 2010 Sep;84(18):9427-38. doi: 10.1128/JVI.00373-10. Epub 2010 Jul 14.

11.

In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Hurt AC, Holien JK, Barr IG.

Antimicrob Agents Chemother. 2009 Oct;53(10):4433-40. doi: 10.1128/AAC.00334-09. Epub 2009 Aug 3.

12.

Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L.

Antimicrob Agents Chemother. 2008 Dec;52(12):4331-7. doi: 10.1128/AAC.00506-08. Epub 2008 Sep 29.

13.

Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance.

Davey VJ, Glass RJ, Min HJ, Beyeler WE, Glass LM.

PLoS One. 2008 Jul 2;3(7):e2606. doi: 10.1371/journal.pone.0002606.

14.

Genetic strategy to prevent influenza virus infections in animals.

Chen J, Chen SC, Stern P, Scott BB, Lois C.

J Infect Dis. 2008 Feb 15;197 Suppl 1:S25-8. doi: 10.1086/524987. Review.

15.

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1).

Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, Dziuba N, Holbrook MR, Zhang L, Kilpatrick JM, Arnold CS, Paessler S.

Virology. 2008 Apr 25;374(1):198-209. doi: 10.1016/j.virol.2007.12.029. Epub 2008 Jan 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk